Moreover, another way to increase therapy outcome for osteosarcoma by increasing the targeting capacity of the drug and decreasing or reversing the tumor-associated immunosuppression was proved to be achieved by the self-assembly of an OXA-based Pt(IV) prodrug amphiphile, namely Lipo-OXA-ALN, in which alendronate (ALN) acts as a targeting agent for osteosarcoma cells [43]. This evidence concerns the gene ARLN and osteosarcoma.